miR‑490‑3p functions as a tumor suppressor in glioma by inhibiting high‑mobility group AT‑hook 2 expression

Zhang,Fang; Wu,Anhao; Wang,Yinhui; Liu,Jianmin

doi:10.3892/etm.2019.7606

miR‑490‑3p functions as a tumor suppressor in glioma by inhibiting high‑mobility group AT‑hook 2 expression

Authors:
- Fang Zhang
- Anhao Wu
- Yinhui Wang
- Jianmin Liu
View Affiliations

Affiliations: Department of Tumor 2 Families, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, P.R. China, Department of Thoracic Surgery Ward II, Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650100, P.R. China, Department of Clinical Medicine, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510400, P.R. China
Published online on: May 23, 2019 https://doi.org/10.3892/etm.2019.7606
Pages: 664-670
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is one of the most common types of malignant cancer and the significance of microRNAs (miRNAs) in cancer therapy has been demonstrated. In the current study, miR‑490‑3p expression was significantly downregulated in glioma tissue and cell lines. Overexpression of miR‑490‑3p inhibited glioma cell proliferation and migration in vitro. In addition, the high‑mobility group AT‑hook 2 (HMGA2) was identified as a candidate target gene of miR‑490‑3p. The current study demonstrated that miR‑490‑3p mimic could inhibit HMGA2 protein expression in glioma cells. In addition, correlation analysis demonstrated that miR‑490‑3p and HMGA2 expression was inversely correlated in glioma tissues. Furthermore, the inhibitory effect of miR‑490‑3p mimic on cell proliferation and migration was partially reversed by the overexpression of HMGA2. Taken together, these results suggest that miR‑490‑3p may have a tumor suppressive role in glioma and therefore miR‑490‑3p may be a new target for the treatment of glioma.

View Figures

View References

1	Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J and Brandes A; RARECARE working group, : Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 48:1532–1542. 2012. View Article : Google Scholar : PubMed/NCBI
2	Chhabda S, Carney O, D'Arco F, Jacques TS and Mankad K: The 2016 world health organization classification of tumours of the central nervous system: What the paediatric neuroradiologist needs to know. Quant Imaging Med Surg. 6:486–489. 2016. View Article : Google Scholar : PubMed/NCBI
3	Mittal S, Pradhan S and Srivastava T: Recent advances in targeted therapy for glioblastoma. Expert Rev Neurother. 15:935–946. 2015. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
6	Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
8	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
9	Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP and Romani M: MicroRNA in glioblastoma: An overview. Int J Genomics. 2017:76390842017. View Article : Google Scholar : PubMed/NCBI
10	Liu X, He B, Xu T, Pan Y, Hu X, Chen X and Wang S: MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer. J Cancer. 9:1218–1230. 2018. View Article : Google Scholar : PubMed/NCBI
11	Tian J, Xu YY, Li L and Hao Q: MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res. 9:1127–1138. 2017.PubMed/NCBI
12	Tang B, Liu C, Zhang QM and Ni M: Decreased expression of miR-490-3p in osteosarcoma and its clinical significance. Eur Rev Med Pharmacol Sci. 21:246–251. 2017.PubMed/NCBI
13	Liu W, Xu G, Liu H and Li T: MicroRNA-490-3p regulates cell proliferation and apoptosis by targeting HMGA2 in osteosarcoma. FEBS Lett. 589:3148–3153. 2015. View Article : Google Scholar : PubMed/NCBI
14	Hammond SM and Sharpless NE: HMGA2, microRNAs and stem cell aging. Cell. 135:1013–1016. 2008. View Article : Google Scholar : PubMed/NCBI
15	Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S: Increased expression of high mobility group A proteins in lung cancer. J Pathol. 209:206–212. 2006. View Article : Google Scholar : PubMed/NCBI
16	Liu B, Pang B, Hou X, Fan H, Liang N, Zheng S, Feng B, Liu W, Guo H, Xu S and Pang Q: Expression of high mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. Hum Pathol. 45:1752–1758. 2014. View Article : Google Scholar : PubMed/NCBI
17	Xu L, Du B, Lu QJ, Fan XW, Tang K, Yang L and Liao WL: miR-541 suppresses proliferation and invasion of squamous cell lung carcinoma cell lines via directly targeting high-mobility group AT-hook 2. Cancer Med. 7:2581–2591. 2018. View Article : Google Scholar : PubMed/NCBI
18	Zhao H, Zhao H, Xia X and Liu X: MicroRNA-599 targets high-mobility group AT-hook 2 to inhibit cell proliferation and invasion in clear cell renal carcinoma. Mol Med Rep. 17:7451–7459. 2018.PubMed/NCBI
19	Komori T: The 2016 WHO classification of tumours of the central nervous system: The major points of revision. Neurol Med Chir (Tokyo). 57:301–311. 2017. View Article : Google Scholar : PubMed/NCBI
20	Karnofsky DA and Burchenal JH: Evaluation of chemotherapeutic agents. In: The Clinical Evaluation of Chemotherapeutic Agents in Cancer. MacLeod CM (ed). Columbia University Press; New York, NY: pp. 191–205. 1949
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
24	Zhang D, Liu Z, Zheng N, Wu H, Zhang Z and Xu J: MiR-30b-5p modulates glioma cell proliferation by direct targeting MTDH. Saudi J Biol Sci. 25:947–952. 2018. View Article : Google Scholar : PubMed/NCBI
25	Ding CQ, Deng WS, Yin XF and Ding XD: MiR-122 inhibits cell proliferation and induces apoptosis by targeting runt-related transcription factors 2 in human glioma. Eur Rev Med Pharmacol Sci. 22:4925–4933. 2018.PubMed/NCBI
26	Chiou SH, Dorsch M, Kusch E, Naranjo S, Kozak MM, Koong AC, Winslow MM and Grüner BM: Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep. 8:140082018. View Article : Google Scholar : PubMed/NCBI
27	Hawsawi O, Henderson V, Burton LJ, Dougan J, Nagappan P and Odero-Marah V: High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer. Biochem Biophys Res Commun. 504:196–202. 2018. View Article : Google Scholar : PubMed/NCBI
28	Kaur H, Ali SZ, Huey L, Hütt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG and Raabe EH: The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 377:55–64. 2016. View Article : Google Scholar : PubMed/NCBI
29	Li Y, Zhang X, Chen D and Ma C: Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2. Tumour Biol. 37:8107–8119. 2016. View Article : Google Scholar : PubMed/NCBI